Shares of InVitae Corp (NASDAQ:NVTA) have received a consensus rating of “Hold” from the six analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $15.00.
NVTA has been the topic of several recent analyst reports. Benchmark Co. reaffirmed a “buy” rating and set a $16.00 price target (up previously from $11.00) on shares of InVitae Corp in a research report on Monday, April 3rd. ValuEngine cut InVitae Corp from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 23rd.
Hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC bought a new stake in shares of InVitae Corp during the fourth quarter valued at approximately $3,970,000. Renaissance Technologies LLC acquired a new stake in shares of InVitae Corp during the fourth quarter worth approximately $879,000. Vanguard Group Inc. increased its stake in shares of InVitae Corp by 9.8% in the first quarter. Vanguard Group Inc. now owns 1,206,266 shares of the medical research company’s stock worth $13,341,000 after buying an additional 107,775 shares during the last quarter. Teton Advisors Inc. acquired a new stake in shares of InVitae Corp during the first quarter worth approximately $564,000. Finally, TIAA CREF Investment Management LLC increased its stake in shares of InVitae Corp by 32.8% in the first quarter. TIAA CREF Investment Management LLC now owns 121,549 shares of the medical research company’s stock worth $1,344,000 after buying an additional 30,039 shares during the last quarter.
Shares of InVitae Corp (NASDAQ:NVTA) traded up 2.582% on Monday, hitting $9.735. 193,327 shares of the stock traded hands. The firm’s 50-day moving average is $9.21 and its 200 day moving average is $9.50. The firm’s market cap is $411.93 million. InVitae Corp has a 12-month low of $5.76 and a 12-month high of $11.88.
InVitae Corp (NASDAQ:NVTA) last issued its earnings results on Tuesday, May 9th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.04. The firm had revenue of $10.34 million for the quarter, compared to analysts’ expectations of $10.90 million. InVitae Corp had a negative return on equity of 119.10% and a negative net margin of 260.48%. The company’s revenue was up 161.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.80) earnings per share. Equities research analysts forecast that InVitae Corp will post ($2.37) EPS for the current fiscal year.
InVitae Corp Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.